Investigating how early genetic changes affect prostate cancer progression and treatment resistance
The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11167102
This study is looking at how certain early genetic changes in prostate cancer, especially in the SPOP gene, affect how the cancer grows and responds to treatment, and it involves analyzing samples from patients to find out why some cancers become resistant to therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11167102 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of early genetic alterations in prostate cancer and how they influence the disease's progression and response to treatment. By examining specific mutations, particularly in the SPOP gene, the study aims to uncover mechanisms that maintain the cancer's lineage and contribute to resistance against therapies. Patients will be involved through the analysis of human prostate cancer samples, and novel models will be used to simulate disease progression. The ultimate goal is to identify distinct pathways that lead to treatment-resistant forms of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with prostate cancer, particularly those with early-stage disease or specific genetic mutations.
Not a fit: Patients with advanced prostate cancer who do not have the relevant genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for prostate cancer by targeting specific genetic alterations.
How similar studies have performed: Previous research has shown promising results in understanding genetic alterations in prostate cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARBIERI, CHRISTOPHER E — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: BARBIERI, CHRISTOPHER E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer